Gregory P Adams

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi request reprint Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers
    Gregory P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 12:1599-605. 2006
  2. ncbi request reprint Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules
    G P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Nucl Med Biol 27:339-46. 2000
  3. ncbi request reprint Generating improved single-chain Fv molecules for tumor targeting
    G P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Immunol Methods 231:249-60. 1999
  4. ncbi request reprint A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice
    Gregory P Adams
    Divison of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 64:6200-6. 2004
  5. pmc Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies
    Matthew K Robinson
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 14:875-82. 2008
  6. ncbi request reprint Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning
    Qing An Yuan
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    Cancer Immunol Immunother 57:367-78. 2008
  7. ncbi request reprint Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer
    Qing An Yuan
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Mol Cancer Ther 5:2096-105. 2006
  8. pmc Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors
    Stephen I Rudnick
    Developmental Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania
    Cancer Res 71:2250-9. 2011
  9. ncbi request reprint High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules
    G P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 61:4750-5. 2001
  10. pmc A rapid method to regenerate piezoelectric microcantilever sensors (PEMS)
    LiNa Loo
    Developmental Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    Sensors (Basel) 11:5520-8. 2011

Collaborators

Detail Information

Publications37

  1. ncbi request reprint Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers
    Gregory P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 12:1599-605. 2006
    ..25 %ID/g). These findings substantiate that the improved tumor retention of (sFv')2 homodimers over sFv monomers results from the availability of dual binding sites rather than from the slower systemic clearance of homodimers...
  2. ncbi request reprint Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules
    G P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Nucl Med Biol 27:339-46. 2000
    ..46) indicating that antigen-specific targeting was not a factor. This suggests that the physical half-life of (213)Bi may be too brief to be effectively paired with systemically-administered diabody or scFv molecules...
  3. ncbi request reprint Generating improved single-chain Fv molecules for tumor targeting
    G P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Immunol Methods 231:249-60. 1999
    ..In this review, we describe a number of these methods and discuss some of the characteristics that may belong to an optimal antibody-based targeting vehicle...
  4. ncbi request reprint A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice
    Gregory P Adams
    Divison of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 64:6200-6. 2004
    ..The maximum tolerated dose was also dependent on the tumor xenograft model used. These studies indicate that genetically engineered antitumor diabody molecules can be used as effective vehicles for radioimmunotherapy...
  5. pmc Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies
    Matthew K Robinson
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 14:875-82. 2008
    ..We hypothesized that the C6.5 diabody, a noncovalent anti-HER2 single-chain Fv dimer, would be an ideal radioisotope carrier for the radioimmunotherapy of established tumors using the short-lived alpha-emitting radioisotope (211)At...
  6. ncbi request reprint Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning
    Qing An Yuan
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    Cancer Immunol Immunother 57:367-78. 2008
    ....
  7. ncbi request reprint Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer
    Qing An Yuan
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Mol Cancer Ther 5:2096-105. 2006
    ..These results indicate that antibody-based constructs may provide a highly specific means of targeting MISIIR on human ovarian carcinoma cells for the purpose of diagnosing and treating this disease...
  8. pmc Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors
    Stephen I Rudnick
    Developmental Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania
    Cancer Res 71:2250-9. 2011
    ..Together, our findings offer insights into how to optimize the ability of therapeutic antibodies to penetrate tumors...
  9. ncbi request reprint High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules
    G P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 61:4750-5. 2001
    ..These results indicate that antibody-based molecules with extremely high affinity have impaired tumor penetration properties that must be considered in the design of antibody-based cancer therapies...
  10. pmc A rapid method to regenerate piezoelectric microcantilever sensors (PEMS)
    LiNa Loo
    Developmental Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    Sensors (Basel) 11:5520-8. 2011
    ..This simple regeneration protocol both minimized the time required to re-conjugate the probe and preserved the density of probe immobilized on PEMS surface, yielding identical biosensor sensitivity over a series of assays...
  11. ncbi request reprint Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody
    Matthew K Robinson
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer Res 65:1471-8. 2005
    ..Thus, diabodies may represent an effective molecular structure for development of novel PET radiotracers...
  12. ncbi request reprint Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration
    G P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Immunol Immunother 40:299-306. 1995
    ..06 microgram/ml, at the 48-h point. These results suggest that multiple high-dose administrations of radiolabeled 741F8 (sFv')2 may lead to the selective tumor localization of therapeutic radiation doses...
  13. pmc Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens
    Jiping Zhang
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    FASEB J 27:581-9. 2013
    ..15% (mutant E3), respectively. Thus, we have identified and affinity-maturated the first scFv antibody capable of inhibiting FAP function. This scFv antibody has the potential to disrupt the role of FAP in tumor invasion and metastasis...
  14. pmc Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma
    Peirong Chen
    Immune Cell Development and Host Defense Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 8:e61446. 2013
    ..These results provide a foundation for the in vivo exploitation of IFN-γ-driven tumoricidal activity in RCC...
  15. pmc Affinity and avidity in antibody-based tumor targeting
    Stephen I Rudnick
    Molecular Medicine Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Biother Radiopharm 24:155-61. 2009
    ..As opposed to the trend of simply increasing affinity to increase efficacy, novel strategies that increase avidity and broaden specificity have made significant progress in tumor targeting...
  16. pmc Highly sensitive detection of HER2 extracellular domain in the serum of breast cancer patients by piezoelectric microcantilevers
    LiNa Loo
    Developmental Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, United States
    Anal Chem 83:3392-7. 2011
    ..This indicates that PEMS-based biosensors provide a potentially effective tool for biomarker detection...
  17. ncbi request reprint Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity
    A M McCall
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Immunol 166:6112-7. 2001
    ....
  18. ncbi request reprint A Rapid Method to Regenerate Piezoelectric Microcantilever Sensors (PEMS)
    LiNa Loo
    Developmental Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111
    Sensors (Basel) 11:5520-8. 2011
    ..This simple regeneration protocol both minimized the time required to re-conjugate the probe and preserved the density of probe immobilized on PEMS surface, yielding identical biosensor sensitivity over a series of assays...
  19. ncbi request reprint Monoclonal antibody therapy of cancer
    Gregory P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111, USA
    Nat Biotechnol 23:1147-57. 2005
    ..Progress in the clinical use of radioimmunoconjugates remains hindered by complexity of administration, toxicity concerns and insufficiently selective tumor targeting...
  20. ncbi request reprint Monoclonal antibody therapy for cancer
    Margaret von Mehren
    Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, Pennsylvania 19111, USA
    Annu Rev Med 54:343-69. 2003
    ..Other structural manipulations that improve the selective targeting properties and rapid systemic clearance of immunoconjugates should lead to the design of effective new treatments, particularly for solid tumors...
  21. ncbi request reprint Isolation of scFvs to in vitro produced extracellular domains of EGFR family members
    Eva Horak
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Biother Radiopharm 20:603-13. 2005
    ..These scFvs provide a valuable and potentially clinically relevant panel of agents to target the members of the EGFR family...
  22. ncbi request reprint Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies
    G P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 58:485-90. 1998
    ..These results indicate that affinity can significantly impact the in vivo tumor-specific retention of scFv molecules...
  23. ncbi request reprint Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII
    L M Weiner
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphi, PA 19111
    Cancer Immunol Immunother 42:141-50. 1996
    ..Although PMN may serve as a significant competitive binding pool of systemically administered 2B1 in vivo, the therapeutic potential of the targeted cytotoxicity properties of this bsmAb should not be compromised...
  24. ncbi request reprint Improving the tumor specificity and retention of antibody-based molecules
    G P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    In Vivo 12:11-21. 1998
    ..g., by altering the clearance of unbound antibody or radiolabel), and the selection of radioisotopes and labeling methods which are more stable in vivo or better suited to the target application...
  25. pmc Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu
    G P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Br J Cancer 77:1405-12. 1998
    ..In conclusion, the diabody format provides the C6.5 molecule with a distinct in vitro and in vivo targeting advantage and has promise as a delivery vehicle for therapeutic agents...
  26. doi request reprint Antibody engineering principles and applications
    LiNa Loo
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer J 14:149-53. 2008
    ..This review provides an overview of the techniques that we expect will have the greatest impact on the field of antibody engineering...
  27. ncbi request reprint Radioimmunotherapy with engineered antibodies
    Maria G Russeva
    Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Expert Opin Biol Ther 4:217-31. 2004
    ..This review addresses the recent advances in antibody engineering and in RAIT strategies that have brought this field to the brink of success...
  28. pmc Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective
    Siddharth Balachandran
    Immune Cell Development and Host Defense Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Interferon Cytokine Res 33:171-80. 2013
    ..Although this review will focus on exploiting IFN-γ-induced necrosis for treatment of renal cell carcinoma, these approaches are also directly applicable to several human cancers in which IFNs have shown therapeutic potential...
  29. pmc Label-free, all-electrical, in situ human epidermal growth receptor 2 detection
    Joseph A Capobianco
    Department of Materials Science and Engineering, Drexel University, Philadelphia, Pennsylvania 19104, USA
    Rev Sci Instrum 79:076101. 2008
    ..Coupled with a scFv with a KD of 3.4 x 10(-8)M, the MPS-insulated PMN-PT/tin PEMS 560 microm long and 720 microm wide exhibited a Her2 concentration sensitivity of 5 ng/ml in a background of 1 mg/ml BSA...
  30. pmc Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro
    M K Robinson
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA mk_robinson fccc edu
    Br J Cancer 99:1415-25. 2008
    ....
  31. pmc Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation
    Anna Sukhanova
    Program in Developmental Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Discov 3:96-111. 2013
    ..Analysis of Nsdhl-deficient Bpa(1H/+) mice confirmed dramatic and selective loss of internalized platelet-derived growth factor receptor in fibroblasts, and reduced activation of EGFR and its effectors in regions of skin lacking NSDHL...
  32. ncbi request reprint Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scanner
    Dinko E González Trotter
    Functional Imaging Laboratory, General Electric Global Research, Niskayuna, NY 12309, USA
    J Nucl Med 45:1237-44. 2004
    ..The recovery coefficients found from the phantom data were applied to in vivo (124)I anti-HER2/neu C6.5 diabody PET data and compared with necropsy biodistribution data from the same tumor-bearing immunodeficient mouse...
  33. ncbi request reprint T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity
    Markus Chmielewski
    Klinik I fur Innere Medizin, Tumorgenetik, Kliniken der Universität zu Köln, and Center for Molecular Medicine Cologne, Koln, Germany
    J Immunol 173:7647-53. 2004
    ....
  34. ncbi request reprint In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics
    Ann Charlott Steffen
    Unit of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Cancer Biother Radiopharm 20:239-48. 2005
    ..125I was used in this study as a surrogate marker for the diagnostically relevant radioisotopes 123I for single photon emission computed tomography (SPECT)/gamma-camera imaging and 124I for positron emission tomography (PET)...
  35. ncbi request reprint Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice
    Ann Charlott Steffen
    Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Eur J Nucl Med Mol Imaging 33:631-8. 2006
    ..The purpose of this study was to investigate the in vivo properties of the new targeting agent...
  36. ncbi request reprint Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells
    Yu Zhou
    Department of Anesthesia and Pharmaceutical Chemistry, University of California, San Francisco Rm 3C 38, San Francisco General Hospital, 1001 Potrero Ave, San Francisco, CA 94110, USA
    J Mol Biol 371:934-47. 2007
    ..The results show the importance of antibody fragment density on nanoparticle uptake, and suggest that engineering ultrahigh affinity scFv may be unnecessary for optimal nanoparticle targeting...
  37. ncbi request reprint Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule
    Erika Nordberg
    Rudbeck Laboratory, Department of Oncology, Radiology and Clinical Immunology, Biomedical Radiation Sciences, Uppsala University, SE 751 85 Uppsala, Sweden
    Nucl Med Biol 34:609-18. 2007
    ..This new and small molecule is aimed for applications in nuclear medicine. The natural ligand epidermal growth factor (EGF) and the antibody cetuximab were studied for comparison...